Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICP 033

Next Previous
X
Search
Drug Profile

ICP 033

Alternative Names: ICP-033

Latest Information Update: 24 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoCare Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Discoidin domain receptor 1 antagonists; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 25 Feb 2022 Phase-I clinical trials in Solid tumours (Inoperable/unresectable, Late-stage disease, Metastatic disease) in China (PO) (NCT05367232)
  • 29 Aug 2021 National Medical Products Administration (NMPA) approves the IND application for ICP 033 in Cancer
  • 06 Jun 2021 InnoCare Pharma announces intention to file IND application for Solid tumours to NMPA in China in first half of 2021 (InnoCare Pharma website, June 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top